Citations

Clear

4610 citation(s) found for "Lu, Brian".

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
Munshi, Nikhil C. , Bergsagel, P. Leif , Shaughnessy, John D. , Palumbo, Antonio , Durie, Brian G.M. , Fonseca, Rafaël , Stewart, A. Keith, Harousseau, Jean‐Luc, Dimopoulos, Meletios Α. , Hájek, Roman , Sezer, Orhan , Kyle, Robert A. , Sonneveld, Pieter , Cavo, Michèle , Rajkumar, S. Vincent , Miguel, Jesús F. San , Crowley, John, Avet‐Loiseau, Hervé , 2, on behalf of the International Myeloma Workshop Consensus Panel, Bergsagel, P. Leif , García‐Sánz, Ramón , Moreau, Philippe , Anderson, Kenneth C. , Stewart, A. Keith, Jagannath, Sundar , 2, on behalf of the International Myeloma Workshop Consensus Panel, Hajek, Roman , Rajkumar, S Vincent , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Garcia-Sanz, Ramon , Fonseca, Rafael

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4696-4700

10.1182/blood-2010-10-300970 | PMID 21292777 Get It

AbstractA panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy but to prognosticate. There is general consensus that risk stratification is applicable to newly diagnosed patients; however, some genetic abnormalities characteristic of poor outcome at diagnosis may suggest poor outcome if only detected at the time of relapse. Thus, in good-risk patients, it is necessary to evaluate for high-risk features at relapse. Although detection of any cytogenetic abnormality is considered to suggest higher-risk disease, the specific abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion, t(4;14) and del17p, and detection by fluorescence in situ hybridization of t(4;14), t(14;16), and del17p. Detection of 13q deletion by fluorescence in situ hybridization only, in absence of other abnormalities, is not considered a high-risk feature. High serum β2-microglobulin level and International Staging System stages II and III, incorporating high β2-microglobulin and low albumin, are considered to predict higher risk disease. There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations.
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
Rajkumar, S. Vincent , Harousseau, Jean‐Luc, Durie, Brian G.M. , Dimopoulos, Meletios Α. , Kyle, Robert A. , Bladé, Joan , Richardson, Paul G. , Orlowski, Robert Z. , Avet‐Loiseau, Hervé , Palumbo, Antonio , Zonder, Jeffrey A. , Vesole, David H., Sezer, Orhan , Munshi, Nikhil C. , Miguel, Jesús F. San , 1, on behalf of the International Myeloma Workshop Consensus Panel, Cavo, Michèle , García‐Sánz, Ramón , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Orlowski, Robert Z. , Siegel, David S. , Jagannath, Sundar , Facon, Thierry T.F. , Lonial, Sagar , Ludwig, Heinz , 1, on behalf of the International Myeloma Workshop Consensus Panel, Rajkumar, S Vincent , Dimopoulos, Meletios A , San-Miguel, Jesus , Garcia-Sanz, Ramon

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4691-4695

10.1182/blood-2010-10-299487 | PMID 21292775 Get It

Abstract It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results in myeloma. The goal of the International Myeloma Workshop Consensus Panel 1 was to develop a set of guidelines for the uniform reporting of clinical trial results in myeloma. This paper provides a summary of the current response criteria in myeloma, detailed definitions for patient populations, lines of therapy, and specific endpoints. We propose that future clinical trials in myeloma follow the guidelines for reporting results proposed in this manuscript.
Do old HLA and mitochondrial DNA variants associate with demyelination types in young patients?
Kálmán, Bernadette , Weinshenker, Brian G. , Weinshenker, Brian G

Mayo Clinic

Neurology | February 3, 2011 | Volume: 76 | Issue: 9 | Pages: 768-769

10.1212/wnl.0b013e31820e7bfc | PMID 21288985 Get It

Clinical Reasoning: A 10-month-old boy with myoclonic status epilepticus
Dhamija, Radhika , Moseley, Brian D. , Wirrell, Elaine , Dhamija, Radhika

Mayo Clinic

Neurology | January 31, 2011 | Volume: 76 | Issue: 5 | Pages: No page available

10.1212/wnl.0b013e31820a0d39 | PMID 21282586 Get It

Effects of Insulin Sensitivity, Body Composition, and Fitness on Lipoprotein Particle Sizes and Concentrations Determined by Nuclear Magnetic Resonance
Irving, Brian A. , Srinivasan, Manivannan , Nair, K. Sreekumaran

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 27, 2011 | Volume: 96 | Issue: 4 | Pages: E713-E718

10.1210/jc.2010-2170 | PMID 21270325 Get It

AbstractContext:Insulin resistance has been reported to be associated with development of atherogenic dyslipidemia. However, the confounding effects that obesity and low levels of cardiorespiratory fitness have on the relationship between insulin resistance and the development of atherogenic dyslipidemia remain to be adequately addressed.Objective:This study sought to examine the independent and combined effects of insulin sensitivity, body composition, and cardiorespiratory fitness on lipoprotein particle sizes and concentrations.Methods:Eight-four healthy, nondiabetic men (n = 43) and women (n = 41) were studied. The participants had a wide range of ages (18–30 and 65–80 yr), body composition (7.2–52.8% fat), and cardiorespiratory fitness (VO2 peak, 13.5–66.2 ml/kg·min). Body composition, cardiorespiratory fitness, insulin sensitivity, and lipoprotein particle profiles were assessed using dual-energy x-ray absorptiometry, cardiopulmonary exercise testing, a hyperinsulinemic-euglycemic clamp, and nuclear magnetic resonance spectroscopy, respectively.Results:Low levels of insulin sensitivity and cardiorespiratory fitness and higher levels of adiposity were associated with the accumulation of small, dense, low-density lipoprotein particles; small high-density lipoprotein particles; triglycerides; and very low-density lipoprotein particles. Multivariate forward-stepwise regression revealed that higher levels of adiposity, in particular truncal fat, were the strongest predictor of the lipoprotein particle size and concentration data, followed by insulin sensitivity.Conclusions:As expected, the accumulation of atherogenic lipoprotein particles (e.g. small, dense, low-density lipoprotein particles and small, high-density lipoprotein particles) was associated with low levels of insulin sensitivity, cardiorespiratory fitness, and higher levels of adiposity. However, multivariate forward-stepwise regression revealed that triglycerides, followed by truncal fat mass, were the strongest predictors of the lipoprotein particle size and concentration data.
Bro1 binding to Snf7 regulates ESCRT-III membrane scission activity in yeast
Wemmer, Megan, Azmi, Ishara F. , Davies, Brian A., Katzmann, David J. , Odorizzi, Greg , West, Matthew

Mayo Clinic

Journal of Cell Biology | January 24, 2011 | Volume: 192 | Issue: 2 | Pages: 295-306

10.1083/jcb.201007018 | PMID 21263029 Get It

Endosomal sorting complexes required for transport (ESCRTs) promote the invagination of vesicles into the lumen of endosomes, the budding of enveloped viruses, and the separation of cells during cytokinesis. These processes share a topologically similar membrane scission event facilitated by ESCRT-III assembly at the cytosolic surface of the membrane. The Snf7 subunit of ESCRT-III in yeast binds directly to an auxiliary protein, Bro1. Like ESCRT-III, Bro1 is required for the formation of intralumenal vesicles at endosomes, but its role in membrane scission is unknown. We show that overexpression of Bro1 or its N-terminal Bro1 domain that binds Snf7 enhances the stability of ESCRT-III by inhibiting Vps4-mediated disassembly in vivo and in vitro. This stabilization effect correlates with a reduced frequency in the detachment of intralumenal vesicles as observed by electron tomography, implicating Bro1 as a regulator of ESCRT-III disassembly and membrane scission activity.
Increasing Liquid Chromatography–Tandem Mass Spectrometry Throughput by Mass Tagging: A Sample-Multiplexed High-Throughput Assay for 25-Hydroxyvitamin D2 and D3
Netzel, Brian C., Cradic, Kendall W, Bro, Eric T., Girtman, Adam B, Cyr, Richard C, Grebe, Stefan K., Girtman, Adam, Singh, Ravinder J.

Mayo Clinic

Clinical Chemistry | January 18, 2011 | Volume: 57 | Issue: 3 | Pages: 431-440

10.1373/clinchem.2010.157115 | PMID 21245371 Get It

BACKGROUND The limits of chromatographic speed and mechanical frontend capabilities have been reached for many high-volume liquid chromatography–tandem mass spectrometry (LC-MS/MS) tests, curtailing the maximal achievable sample throughput. To overcome these boundaries, we developed and validated a derivatization-based sample-multiplex LC-MS/MS assay for detection of 25-hydroxyvitamins D2 and D3 [25(OH)D2 and 25(OH)D3], which increased sample throughput 5-fold. METHODS After separate derivatization with 1 of 5 different triazoline-diones (TADs), 5 calibrators, controls, or patient specimens were combined and injected together into an LC-MS/MS. On the basis of mass differences between TADs, the MS/MS quantified analyte and stable isotope internal standards for 25(OH)D2 and 25(OH)D3 for each respective multiplexed sample within the injection. Limits of detection and quantification, spiked recovery, linearity, imprecision, and patient results were determined and compared against our standard LC-MS/MS assay. RESULTS TAD multiplexing increased throughput on an LC-quadruplexed LC-MS/MS system from 60 samples/h to 300 samples/h. Limits of detection and quantification were 4.9 nmol/L [2 μg/L, 25(OH)D2], 2.2 nmol/L [0.9 μg/L, 25(OH)D3], and 10 nmol/L [4 μg/L, 25(OH)D2], 5 nmol/L [2 μg/L, 25(OH)D3], respectively. The assay was linear to 250 nmol/L (100 μg/L). Interassay CVs across the reportable range were 3.7%–15.2%. Spiked recoveries were 94%–119%. The method comparison with the standard LC-MS/MS method showed slopes of 0.96 and 0.97 (Deming regression) for 25(OH)D2 (n = 1733) and 25(OH)D3 (n = 7614) (R2=0.96 and 0.97), respectively. CONCLUSIONS Multiplexing samples by differential mass tagging in LC-MS/MS measurement of 25(OH)D2 and 25(OH)D3 allows for reliable quantification, with throughput increased over standard methods by the multiplexing factor.
Pearls & Oy-sters: Clues for spinal dural arteriovenous fistulae
McKeon, Andrew , Lindell, E. Paul , Atkinson, J.L.D. , Weinshenker, Brian G. , Piepgras, D. G., Pittock, Sean J. , Pittock, S J , Weinshenker, Brian G , McKeon, Andrew

Mayo Clinic

Neurology | January 17, 2011 | Volume: 76 | Issue: 3 | Pages: No page available

10.1212/wnl.0b013e3182074a42 | PMID 21242488 Get It

Association of IL2RA p olymorphisms with susceptibility to multiple sclerosis is not explained by missense mutations in IL2RA
Matiello, Marcelo , Weinshenker, Brian G. , Atkinson, Elizabeth J. , Schaefer-Klein, Janet, Kantarci, Orhun H. , Weinshenker, Brian G

Mayo Clinic

Multiple Sclerosis Journal | January 14, 2011 | Volume: 17 | Issue: 5 | Pages: 634-636

10.1177/1352458510394703 | PMID 21239413 Get It

Genome-wide association studies have identified an association between two intronic single nucleotide polymorphisms (SNPs), rs12722489 and rs2104286, in the interleukin-2 receptor alpha-chain gene ( IL2RA) and susceptibility to multiple sclerosis (MS). We studied these SNPs in association with susceptibility to and severity of MS in a population-based cohort of 220 patients from Olmsted County, Minnesota, compared with 442 matched controls. We sequenced the exons, splice sites and 5’ and 3’ untranslated regions in 27 randomly selected MS patients (powered for allele frequency ≥0.04) to search for mutations. No novel missense mutation was identified. Two patients (7.5%) had an exon 2 SNP ( rs4308625) and two patients had an exon 4 SNP ( rs2228149), both synonymous.
Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Abla, Oussama , Weitzman, Sheila, Blay, Jean‐Yves , Abrey, Lauren E. , Neuwelt, Edward A. , Doolittle, Nancy D., Baehring, Joachim M. , Pradhan, Kamnesh R. , Martin, Sheelagh, Guerrera, Michael F., Shah, Shafqat, Ghesquières, Hervé , Silver, Michael, Batchelor, Tracy T. , O’Neill, Brian Patrick , Betensky, Rebecca A. , Blay, Jean-Yves

Mayo Clinic

Clinical Cancer Research | January 12, 2011 | Volume: 17 | Issue: 2 | Pages: 346-352

10.1158/1078-0432.ccr-10-1161 | PMID 21224370 Get It

Abstract Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL was assembled from 10 cancer centers in 3 countries. Results: Twenty-nine patients with a median age of 14 years were identified. Sixteen (55%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or greater. Frontline therapy consisted of chemotherapy only in 20 patients (69%), while 9 (31%) had chemotherapy plus cranial radiotherapy. Most patients received methotrexate (MTX)-based regimens. Overall response rate was 86% (complete remission 69%, partial remission 17%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 61% and 86%, respectively; the 3-year OS was 82%. Univariate analyses were conducted for age (≤14 vs. >14 years), PS (0 or 1 vs. >1), deep brain lesions, MTX dose, primary treatment with chemotherapy alone, intrathecal chemotherapy, and high-dose therapy. Primary treatment with chemotherapy alone was associated with better overall response rates with an odds ratio (OR) of 0.125 (P = 0.02). There was a marginally significant relationship between higher doses of MTX and response (OR = 1.5, P = 0.06). ECOG-PS of 0 to 1 was the only factor associated with better outcome with hazard ratios of 0.136 (P = 0.017) and 0.073 (P = 0.033) for PFS and OS, respectively. Conclusion: This is the largest series collected of pediatric PCNSL. The outcome of children and adolescents seems to be better than in adults. PS of 0 to 1 is associated with better survival. Clin Cancer Res; 17(2); 346–52. ©2011 AACR.